You are here: Home » Reuters » News
Business Standard

Novo Nordisk bids $3.1 billion for Belgian biotech group Ablynx

Reuters  |  BRUSSELS 

By Robert-Jan Bartunek and Jacob Gronholt-PedersenBRUSSELS (Reuters) - Denmark's Novo Nordisk, the world's biggest maker of insulin, has made a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx as it seeks to diversify and strengthen its business for treating rare blood disorders.Novo went public with the offer on Monday after Ablynx rebuffed earlier approaches and analysts predicted the Danish group, whose new chief executive is seeking new products to bolster growth, would need to raise its bid to win and might face counterbidders.The approach comes at a time of renewed ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Mon, January 08 2018. 14:49 IST